A number of analogues of ovine growth hormone (GH), in which regions of the hormone had been deleted, were produced by site-directed mutagenesis, and characterised by radioimmunoassays and radioreceptor assays. These analogues were based on a previously described variant (oGH1) in which an 8-residue extension replaces the N-terminal alanine of pituitary-derived ovine GH. Three analogues with deletions near the N-terminus were studied, with shorter extensions of 7 or 1-2 residues (oGH14, oGH5) or with the N-terminal sequence Ala-Phe-Pro-of pituitary-derived ovine GH replaced by Thr-Met-Ile-Thr-(oGH11). These modifications had little effect on potency in radioimmunoassays based on a polyclonal antibody and five different monoclonal antibodies (MABs), or in a radioreceptor assay, indicating that the N-terminal sequence was not included in the epitope binding to any of the monoclonal antibodies, or a major epitope binding to the polyclonal antibody, or in receptor binding site 1. A variant in which residues 133-139 were deleted retained full binding to 4 of the 5 MABs, suggesting correct folding, but markedly reduced binding to MAB OA16, suggesting that the epitope for this MAB includes some or all of these residues. This variant also failed to displace about 35% of labelled hormone from the polyclonal antibody studied, suggesting that residues 133-139 may be involved in a major epitope for this antibody. This variant showed slightly lower receptor binding activity than ovine GH. Two other deletion variantsoGH1 33-46 (equivalent to the naturally occurring 20K variant of human GH) and oGH1 [180][181][182][183][184][185][186][187][188][189][190][191] (lacking the C-terminal 12 residues) showed poor folding efficiency and solubility, and low binding to all MABs except OA15, which has a linear epitope. The results suggest that these variants were incorrectly folded, but interestingly they did retain some activity in the receptor-binding assay (respectively about 5% and 0·5% of the activity of ovine GH itself).
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INTRODUCTION
Pituitary growth hormone (GH) is a protein hormone comprising a single polypeptide chain of about 190 residues. Sequences are available for a considerable number of mammalian GHs (Wallis 1994 ) and the three-dimensional structures of pig (Abdel-Meguid et al. 1987 ) and human (de Vos et al. 1992 , Chantalat et al. 1995 GHs have been described. In each case the hormone comprises a 4-helix bundle with unusual (up-up-down-down) topology, with two long loops, linking helices 1 and 2 and 3 and 4 respectively. The structure of the complex between human GH (hGH) and a binding protein corresponding to the extracellular domain of its receptor has been determined (de Vos et al. 1992) . This has demonstrated that one molecule of GH binds to two molecules of binding protein via quite distinct sites on the hormone (sites 1 and 2); the receptor dimerisation resulting from this probably plays a crucial role in the signalling mechanism. Extensive studies involving sitedirected mutagenesis (especially homology scanning and alanine scanning) have also provided information about the nature of the hormone-receptor interactions for human GH (Cunningham & Wells 1989 , Cunningham et al. 1991 , Wells et al. 1993 . For GHs from other mammals structural studies are less advanced, although there have been a number of investigations of the effects of altering hormone structure on receptor binding and biological activity (e.g. Rowlinson et al. 1994 , Chen et al. 1995 . Since human GH differs markedly (at about 35% of all residues) from non-primate GHs, extrapolation of results obtained from the human GH-receptor model to GHs of non-primates is not always straightforward.
We have previously described the cloning, expression in Escherichia coli, renaturation and purification of a recombinant ovine GH (oGH) variant (oGH1) with an extended N-terminal sequence ). This has been used as the basis of a number of studies in which individual residues have been changed by site-directed mutagenesis, in order to observe effects on immunological, receptorbinding and biological properties (Giles et al. 1995 , Lioupis et al. 1995 , 1996 . We have also used this system to produce GH variants in which parts of the polypeptide have been deleted. Production and characterisation of these variants is described here. The deletions involved sequences in 4 regions of the oGH polypeptide chain selected as interesting on the basis of previous studies.
1. The N-terminal sequence. Removal of the N-terminal 18-33 residues of rat GH by tripeptidyl aminopeptidase had only a moderate effect on biological activity (Doebber et al. 1978) , but a variant of human GH in which the first 7 residues had been deleted was shown to have much reduced activity (Towns et al. 1992) . Residues close to the N-terminus have been identified as being involved in binding site 2 in the human GH-receptor complex (de Vos et al. 1992) . During the course of studying expression of oGH in E. coli we produced a series of variants in which the N-terminal sequence was truncated or modified (Wallis & Wallis 1989 , Wallis et al. 1995 . The 'parent' molecule for the present work (oGH1) came from that study, and has an 8-residue extension replacing the N-terminal alanine of pituitary-derived oGH. It has been characterised in detail previously . Three other variants (oGH14 and oGH5 with shorter extensions of 7 or 1-2 residues, and oGH11 in which the N-terminal sequence Ala-Phe-Pro-of pituitary-derived oGH is replaced by Thr-Met-Ile-Thr-) are characterised here.
2. Residues 33-46. This region is interesting because a naturally occurring hGH variant (20K hGH) is known with an equivalent deletion (Lewis et al. 1980) . This variant has not been characterised for non-mammalian GHs and it was of interest to explore the properties of such a molecule produced artificially.
3. Residues 133-139. This region of GH is very susceptible to cleavage, with production of 2-chain variants which retain activity (e.g. Li & Graf 1974) . The oGH variant produced here lacks 7 residues in this region, but is a single chain molecule.
4. The C-terminal sequence. Various studies have suggested that the C-terminus of GH is relatively unimportant for activity -removal of residues using carboxypeptidase (Harris et al. 1954) or breaking the C-terminal S-S loop (Graf et al. 1975 ) have little effect on activity and a fragment of hGH lacking 57 residues from the C-terminus has been shown to retain low, but significant activity (Li & Graf 1974) . On the other hand, the hGH-receptor model implicates residues fairly close to the C-terminus as being involved in binding site 1. Production and characterisation of a variant of oGH that lacks the C-terminal 12 residues (including the C-terminal disulphide bridge) is described here.
MATERIALS AND METHODS

Expression plasmids
The expression plasmids used in this work were originally derived from plasmid pUC8 (Vieira & Messing 1982) and the cDNA sequence encoding oGH (Warwick et al. 1989) . The production of plasmids pOGHe105, pOGHe111 and pOGHe114, encoding oGH variants oGH5, oGH11 and oGH14 respectively, has been described previously (Wallis & Wallis 1989 , Sami et al. 1990 , Wallis et al. 1995 . Plasmids pOGHe201, pOGHe202 and pOGHe203, encoding proteins oGH1 33-46, oGH1 133-139 and oGH1 180-191 respectively, were derived from plasmid pOGHe101, encoding oGH1 , by site-directed mutagenesis. Plasmids pOGHe201 and pOGHe202 were produced by deletion of appropriate base sequences using a site-directed mutagenesis kit supplied by Amersham International (Amersham, Bucks, UK) according to the supplier's instructions. A singlestranded template for mutagenesis was derived from plasmid pOGHe101 by subcloning the EcoRI/ HindIII fragment containing the oGH1 coding sequence into the multiple cloning site of phage M13 mp18. After mutagenesis the corresponding mutant sequences were subcloned between the EcoRI and HindIII sites in the multiple cloning site of plasmid pUC8 to give plasmids pOGHe201 and pOGHe202. Insertion of a synthetic oligonucleotide dimer into the SauI site (position 609) of plasmid pOGHe101 produced plasmid pOGHe203, in which the codon for amino acid Lys180 was replaced by a stop codon, TAA. This plasmid, therefore, encoded an oGH1 variant terminating after Met179. Appropriate oligonucleotides for deletion mutagenesis were synthesized with an oligonucleotide synthesizer (Applied Biosystems, Warrington, Cheshire, UK). All expression plasmids were cloned into E. coli strain JM109.
The sequences of all these expression plasmids were checked by the dideoxy chain termination procedure (Sanger et al. 1977) using manual sequencing with a Sequenase kit and the conditions described by the supplier (United States Biochemicals, Cleveland, OH, USA). Single-stranded DNA binding protein was added to all plasmid sequencing reactions.
Expression and purification of oGH variants
Purified oGH variants were produced by a procedure based on that developed for oGH1 purification ). Bacteria containing expression plasmids were grown, induced with isopropyl---thiogalactopyranoside (IPTG), and pellets containing insoluble inclusion granules were prepared from them by the published procedure. Inclusion granules were solubilised in 6 M guanidinium chloride and renatured as described for oGH1. Fifty millilitres 6 M guanidinium chloride in ethanolamine-HCl buffer (pH 9·5) were used for every litre of the original culture for oGH5, oGH11, oGH14 and oGH1 133-139. The volume of 6 M guanidinium chloride solution was increased 15-fold for oGH1 33-46 and 4-fold for oGH1 180-191. oGH5, oGH11, oGH14 and oGH1 133-139 were purified by ion-exchange chromatography on DEAE-Sephacel essentially as described for oGH1. However, ion-exchange chromatography with oGH5, oGH11 and oGH1 133-139 was carried out in 0·01 M ethanolamine-HCl buffer (pH 9·0) instead of 0·01 M Tris-HCl buffer (pH 8·0). Ion-exchange chromatography was not carried out with oGH1 33-46 or oGH1 180-191, due to their low solubility. oGH1 33-46 was not further purified after renaturation: the solution was concentrated in an Amicon vacuum filtration unit fitted with a Diaflo Ultrafiltration membrane Type YM (Amicon Ltd, Upper Mill, Stonehouse, Glos, UK) and insoluble material was removed by centrifugation for 5 min at 12 000 g. oGH1 180-191 was further purified by precipitation with 20% ammonium sulphate followed by solubilisation of the insoluble fraction during dialysis against 0·05 M ethanolamine-HCl buffer (pH 9·0).
Determination of protein and oGH variant concentrations
In the early stages of purification, protein concentration was determined by the method of Lowry et al. (1951) , since this is applicable to insoluble material. In purified preparations, containing more than 90% protein as oGH variant, absolute protein concentrations were determined by measuring absorbance at 280 nm, using a value of 7·3 for the absorbance of a 1% solution (Bewley & Li 1972) , except for variant oGH14, where an extra tryptophan in the N-terminal sequence necessitated an adjustment to this value. In final preparations of protein containing less than 90% oGH variant total protein was determined by the method of Bradford (1976) which is less affected by the specific protein being studied than the Lowry method. The oGH variant content of bacteria and of purified preparations was estimated, after subjecting samples to sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (Laemmli 1970) , by scanning Kenacid Blue-stained gels with an LKB Ultroscan XL laser densitometer.
The apparent M r of oGH variants was estimated after electrophoresis on 12·5% SDS-polyacrylamide gels with marker proteins supplied by Sigma Chemical Co., Poole, Dorset, UK.
Radioimmunoassays and radioreceptor assays
The potency of oGH variants was compared with that of oGH1 in radioimmunoassays and in a radioreceptor assay. Recombinant DNA-derived oGH1 and pituitary-derived bovine GH (bGH) have been found to give very similar results in all these assays , and O C Wallis, unpublished data). Radioimmunoassays were carried out by the procedure of Ray & Wallis (1982) using a polyclonal antibody prepared against bGH and a panel of five monoclonal antibodies (MABs). Monoclonal antibodies OA11, OA12, OA15 and OA16 (Aston et al. 1987) were raised against oGH and MAB GH1/D4 was raised against bGH (Thorpe et al. 1990) . Radioreceptor assays were carried out by the method of Cadman & Wallis (1981) using microsomal receptors prepared from pregnant rabbit liver. Results from these assays were expressed as potency relative to that of oGH1.
RESULTS
Expression plasmids
The oGH variants examined in this study are summarised in Table 1 where their positions relative to the 3-dimensional structure are also indicated. The nucleotide sequences coding for oGH variants in the new expression plasmids, pOGHe201-3, were found to be those predicted for plasmids encoding oGH1-like proteins lacking amino acids 33-46, 133-139 and 180-191 respectively (data not shown).
Expression and purification of variants
E. coli JM109 clones containing the new plasmids, pOGHe201-3, and also clones containing plasmids pOGHe105, pOGHe111 or pOGHe114, expressed oGH variant proteins at high levels when grown and induced by IPTG under the conditions described for oGH1 (Fig. 1A) . The lowest expression level was found with oGH5 (10% of the total bacterial protein) and the highest with oGH1 180-191 (60% of the total bacterial protein). After growth and induction of bacteria containing each of the expression plasmids described, all variants were present in an insoluble form within the bacteria.
Variants oGH5, oGH11, oGH14 and oGH1 133-139 were readily renatured and purified by the procedures described in the Materials and Methods section. After DEAE-Sephacel chromatography soluble preparations of these variants were obtained with a purity of over 90% (Fig. 1B) . oGH1 33-46 and oGH1 180-191 could be renatured only in very dilute solutions and the apparent low solubility of these proteins prevented the use of purification procedures which led to concentration of the protein. oGH1 180-191 was obtained at a purity of over 85% by precipitation with 20% ammonium sulphate; preparations of oGH1 33-46 were about 50% pure after the renaturation step and were not purified further (Fig. 1B) . The apparent M r of each variant, calculated from the R F on SDS-polyacrylamide gels, was consistent with the theoretical M r calculated from the DNA-sequence-derived amino acid composition.
Binding properties of variants
Radioimmunoassay -polyclonal antibody In assays with the polyclonal antibody the displacement curves obtained with oGH5, oGH11 and oGH14 were very similar to that obtained with bovine GH (Fig. 2) (relative potencies of 0·7, 1·0 and 1·0 respectively). Both oGH1 133-139 and oGH1 180-191 differed from the other variants studied in that displacement of labelled hormone from the antibody was incomplete (approx. 65% and 45% displacement respectively -see Fig. 2 ). Allowing for this, potency of oGH1 133-139 was about the same as that of oGH1, but that of oGH1 180-191 was about 10-fold lower. The maximum displacement with oGH1 33-46 was the same as that with oGH1 in these assays; displacement of 50% of the labelled bGH required 6 times more of this variant than of oGH1 but calculation of the relative potency was complicated by the observation that the displacement curves were not parallel (Fig. 2) .
Radioimmunoassay -monoclonal antibodies
The results of radioimmunoassay with the five monoclonal antibodies are summarised in Table 2 . It can be seen that alterations in the N-terminus had little effect on potency in these assays while deletion of amino acids 133-139 markedly reduced potency only with MAB OA16. However, oGH1 33-46 did not displace 125 I-labelled bGH from OA11, OA12, OA16 or GH1/D4 at any concentration tested. Potency close to that of oGH1 with this variant was found only with OA15, an antibody which binds to a linear determinant (amino acid residues 94-100) in the GH molecule (Beattie & Holder 1994) . oGH1 180-191 also showed a low potency (less than 12% that of oGH1) with all the MABs tested except OA15.
Radioreceptor assay In the radioreceptor assay the N-terminal variants again showed activity close to those of oGH1 and bGH (potencies relative to bGH were: 0·9 (oGH5), 1·2 (oGH11), 1·3 (oGH14)). Deletion of amino acids 133-139 had only a small effect on receptor binding, reducing potency to 50% of that with oGH1 (Fig. 3A) . However deletion of amino acids 33-46 or of amino acids 180-191 led to marked effects on receptor binding (Fig. 3B) : the potency of oGH1 33-46 in the radioreceptor assay  2. Radioimmunoassays using a polyclonal antibody against bovine GH. Displacement of 125 I-labelled bovine GH by the GH variants indicated in panels (A), (B) and (C) is shown.
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was only about 5% that of oGH1 while that of oGH1 180-191 was ten times lower (about 0·5% that of oGH1).
DISCUSSION
Current ideas about the relationship between structure and activity of pituitary GH are dominated by the availability of a structure for the complex between the human hormone and the external domain of its receptor (de Vos et al. 1992) and by the results of extensive mutagenesis studies on human GH and its receptor (Cunningham & Wells 1989 , Cunningham et al. 1991 , Wells et al. 1993 . The marked differences between human GH and non-primate GHs mean that these studies cannot be automatically extrapolated to nonprimate GHs, on which a number of structurefunction studies have been carried out, including effects of chemical or enzymatic modification and of mutagenesis (e.g. Rowlinson et al. 1994 , Chen et al. 1995 . Several early studies involved removal of sections of the GH molecule, and the present study was intended to explore such deletions further.
Early studies suggested that a substantial part of the N-terminal sequence of rat GH could be removed with retention of significant biological activity (Doebber et al. 1978) . However, others found that removal of 7 (Towns et al. 1992) or 43 (Rowlinson et al. 1996 ) N-terminal residues markedly affects the receptor-binding and biological activities of human GH, while Eppard et al. (1992) showed that removal of the N-terminal 4 residues from bovine GH substantially lowered galactopoietic activity in cows but not the ability to promote growth in hypophysectomised rats. The procedure that we have used to obtain high expression of recombinant ovine GH involved modifying the N-terminus, and resulted in the production of a number of ovine GH variants differing at the N-terminus. The variant characterised in detail previously ), oGH1, has an 8-residue extension at the N-terminus, essentially replacing the N-terminal Ala found in part of pituitary-derived bovine or ovine GH (Wallis 1969 This variant had immunological, receptor binding and growth-promoting activity essentially identical to those of pituitary-derived oGH. We have here characterised 3 additional oGH variants that have slightly different sequences at the N-terminus (Table 1) . In oGH11 a 4-residue extension replaces the first 3 residues (Ala-Phe-Pro) of naturally occurring oGH. Each of these N-terminal variants behaved very similarly to oGH1 and naturally occurring bovine GH in a polyclonal radioimmunoassay (Fig. 2) , and in assays using 5 different monoclonal antibodies (Table 2 ). This indicates that these modifications at the N-terminus do not prevent correct folding of the hormone, and that the epitopes for the 5 MABs do not include the N-terminal sequence. The 3 N-terminal variants were also fully active in the radioreceptor assay, in accord with earlier studies showing that the N-terminal sequence is relatively unimportant for biological activity. However, Cunningham et al. (1991) showed that modification of residues close to the N-terminus in human GH does substantially lower binding of the hormone to the second receptor molecule in receptor dimerisation (i.e. these residues form part of binding site 2). The conditions used for the receptor-binding assay applied here (high molar excess of GH relative to receptor, and probably restricted receptor mobility in the membrane) would be expected to favour binding to site 1. A variant with a modified site 2 but unaltered site 1 may show full binding activity in the radioreceptor assay used, although its ability to dimerise receptors and give a biological response may be lowered. Thus retention of full binding activity in this assay should not be interpreted as indicating retention of biological activity.
Residues 33-46 in oGH correspond to the 15 residues that are deleted from human GH in formation of the naturally occurring variant 20K (Lewis et al. 1980) . Occurrence of this variant in non-primates has not been established, probably because the alternative splice site is not present, and it was interesting to examine whether an artificially produced 20K equivalent for oGH would fold correctly and retain activity. Good expression of oGH1 33-46 was achieved, but yields after folding were low and the solubility of the 'folded' protein was low. Further characterisation suggested that folding of this molecule was defective since binding to a polyclonal antibody was markedly less than that of oGH1 and showed a non-parallel displacement curve (Fig. 2) , and little or no binding to 4 of the 5 monoclonal antibodies tested was detected. Binding to MAB OA15 was similar to that of oGH1; unlike the other four MABs, OA15 is believed to bind to a linear, non-conformational epitope (Beattie & Holder 1994) , which would probably be detectable in the misfolded molecule. Despite these folding problems this variant showed significant activity in the receptor-binding assay, equivalent to about 5% that of oGH1. This is not markedly lower than the corresponding activity of the 20K variant of human GH, which shows receptor-binding activity (in a similar rabbit receptor system) 8-20% that of human GH itself (Sigel et al. 1981) , probably due to lowered affinity at binding site 1 (Wada et al. 1998) . Our results thus indicate that deletion of residues 33-46 from ovine GH gives a molecule retaining significant receptor-binding activity but apparently differing from 20K hGH in its ease of folding. Possibly the many amino acid substitutions that have been accepted during the course of evolution of GH in higher primates (Wallis 1994) include changes facilitating folding of the 20K variant.
In both human and non-primate GHs, the region from residues 130-150 is particularly susceptible to enzymic degradation. Cleavage of human GH with plasmin gave a two-chain form of the molecule, retaining full activity, in which residues 135-140 had been removed (Li & Graf 1974) . Other variants of human GH produced by cleavage in this region appeared to show enhanced biological activity, although their characterisation remains incomplete (e.g. Lewis et al. 1975) . Bovine GH is also susceptible to cleavage in this region, although specificity of cleavage by plasmin is less marked than for human GH (Surowy & Wallis 1983 ). In the 3-dimensional structures of human GH and pig GH, residues 130 to 153 comprise a long loop containing little secondary structure, which would accord with the observed susceptibility to cleavage. In view of these results we produced a variant of oGH1 lacking residues 133-139, the last 6 of which are equivalent to the 6 residues removed from hGH by plasmin. Of course, the resulting variant differed from those produced by enzymic cleavage in that it was a single chain rather than a two-chain molecule. oGH1 133-139 was produced in good yield, and appeared to fold correctly. Its immunological properties were interesting, in that it bound to 4 of the 5 monoclonal antibodies at least as effectively as did oGH1, but showed markedly decreased binding to MAB OA16. Displacement of labelled tracer from the polyclonal antibody was incompleteabout 35% of the total tracer could not be displaced by oGH1 133-139. These results suggest that the epitope for MAB OA16 requires the presence of one or several of residues 133-139, and that this or related epitopes bind to about 35% of the antibody molecules present in the polyclonal antibody. This accords with the demonstration by Aston et al. (1991) that this region is highly antigenic in bovine GH and that polyclonal antibodies that bind to it may enhance the biological activity of GH. MAB OA16 is able to enhance the growth-promoting properties of bovine GH in dwarf mice (Aston et al. 1987) and hypophysectomised rats (Wallis et al. 1987) ; indeed it was the most active enhancing antibody in the latter study. Variant oGH1 133-139 showed receptor-binding activity slightly reduced relative to that of oGH1 or bGH (Fig. 3) . Residues 133-139 are not included in binding site 1 and the slightly decreased activity may reflect some conformational strain imposed on the molecule by removing part of the long loop.
Various studies have suggested that the C-terminal sequence of GH is not essential for biological activity. Thus, the C-terminal residue of bovine GH can be removed by carboxypeptidase without affecting activity (Harris et al. 1954) , and breaking the C-terminal disulphide loop also has no effect on activity (Graf et al. 1975) . Several studies have indicated that if the large fragment of hGH (residues 1-134) produced by plasmin cleavage is separated from the C-terminal fragment (after reduction and alkylation to break the disulphide link) it retains some activity (Li & Graf 1974) , suggesting that the C-terminal third of GH is relatively unimportant for biological activity. In order to explore further the importance of the C-terminal region of oGH we produced a mutant oGH1 180-191 that lacks the C-terminal 12 residues, including the disulphide bridge between Cys181 and Cys189. This variant was produced in E. coli in very high yield, but yields of soluble material after refolding were very poor. In a polyclonal radioimmunoassay the activity of oGH1 180-191 was much lowered relative to oGH1, and about 55% of the labelled tracer could not be displaced at all. Binding to 4 of the 5 MABs tested was very low (Table 2) ; binding to OA15, the MAB thought to detect a linear epitope, was higher, although still less than that of oGH1. The variant did retain some activity in the receptor binding assay, although this was low, and non-parallel. The results obtained with this variant are difficult to interpret. They suggest that a large proportion of the variant was incorrectly folded, which would have affected binding to polyclonal and monoclonal antibodies. Nevertheless, retention of slight receptor-binding activity indicates that removal of the C-terminal 12 residues, including the disulphide bridge, does not completely destroy the binding site(s). Inspection of the structural models available for pig and human GHs (Abdel-Meguid et al. 1987 , de Vos et al. 1992 , Chantalat et al. 1995 indicates that residues 180-183 make up the last turn of helix 4; it may be that removal of this structural component is sufficient to destabilise the molecule and prevent normal folding, although side chains from this turn appear to contribute rather little to the hydrophobic core of the protein.
In conclusion, the studies presented here have provided information about the epitope for MAB OA16. They have established that deletions in the region of the N-terminus, and of residues 133-139 have no deleterious effects on folding of oGH1, whereas deletion of residues 33-46 or 180-191 markedly affect folding efficiency, despite the fact that residues 33-46 are equivalent to the region of the molecule that is missing in the pituitary-derived 20K variant of human GH. In a receptor-binding assay the N-terminal variants showed activity equivalent to that of the parent molecule, and the variant lacking residues 133-139 showed only slightly reduced activity. Despite the poor folding, both oGH1 33-46 and oGH1 180-191 retained significant receptor-binding activity, and in the case of the former this was similar to the activity displayed by the 20K hGH variant in an equivalent assay. However, it may be that the receptor-binding assay used here does not detect binding to site 2 on the GH molecule, and receptor-binding activity cannot therefore be interpreted directly in terms of biological activity. The results presented here provide direct information about expression levels, purification, folding, immunoactivity and receptorbinding activity of these 6 novel oGH variants, but the full biological significance of the results must await the results of detailed study using bioassay systems. 
